Niemann-Pick Disease Types A and B: Early Signs, Diagnosis, and Emerging Treatments

Niemann‑Pick disease (NPD) is a group of rare lysosomal storage disorders caused by SMPD1 mutations (types A/B) leading to acid sphingomyelinase (ASM) deficiency, or NPC1/NPC2 mutations (type C) causing cholesterol trafficking defects.

Type A (Infantile Neurovisceral)

  • Onset: 3–6 months
  • Failure to thrive, hepatosplenomegaly
  • Rapid neurodegeneration: hypotonia, loss of milestones, cherry‑red macula
  • Death by age 2–3

Type B (Chronic Visceral)

  • Onset: childhood/adolescence
  • Hepatosplenomegaly, thrombocytopenia
  • Pulmonary infiltration (interstitial lung disease)
  • Minimal/no neurological involvement
  • Survival into adulthood common

Type C (Distinct Entity)

  • Variable onset (infancy to adulthood)
  • Vertical supranuclear gaze palsy, ataxia, dystonia, dementia
  • Hepatosplenomegaly may be mild

Diagnosis

  • ASM enzyme assay (leukocytes/fibroblasts) for A/B.
  • Genetic testing (SMPD1, NPC1, NPC2) confirms.
  • Filipin staining (cholesterol esterification) for type C.

Management

  • Supportive: nutrition, PT/OT, pulmonary care.
  • Type C: Miglustat (substrate reduction therapy) slows progression.
  • Enzyme replacement (olipudase alfa) approved for type B in some regions.
  • Gene therapy trials ongoing.

Early diagnosis via newborn screening (expanding) enables timely intervention and family counseling.

Genetic Disorders - Related Articles